Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Acquisitions & Divestments (2016 - 2024)

Historic Change in Acquisitions & Divestments for Arcadia Biosciences (RKDA) over the last 8 years, with Q4 2024 value amounting to $2.5 million.

  • Arcadia Biosciences' Change in Acquisitions & Divestments rose 83.93% to $2.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 10083.93%. This contributed to the annual value of $5.0 million for FY2024, which is 10079.94% up from last year.
  • Per Arcadia Biosciences' latest filing, its Change in Acquisitions & Divestments stood at $2.5 million for Q4 2024, which was up 83.93% from $2.5 million recorded in Q4 2023.
  • Arcadia Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $15.2 million during Q1 2020, with a 5-year trough of $1000.0 in Q4 2021.
  • Its 4-year average for Change in Acquisitions & Divestments is $3.9 million, with a median of $2.5 million in 2020.
  • Over the last 5 years, Arcadia Biosciences' Change in Acquisitions & Divestments had its largest YoY gain of 6521.74% in 2020, and its largest YoY loss of 8775.51% in 2020.
  • Arcadia Biosciences' Change in Acquisitions & Divestments (Quarter) stood at $600000.0 in 2020, then plummeted by 99.83% to $1000.0 in 2021, then soared by 250100.0% to $2.5 million in 2023, then increased by 0.84% to $2.5 million in 2024.
  • Its last three reported values are $2.5 million in Q4 2024, $2.5 million for Q4 2023, and $1000.0 during Q4 2021.